Genzyme is kicking TKTX's butt. Genzyme is already approved to sell it's genetic disorder drug in the US. TKTX cannot sell it's "Replagal" in the US for seven more years. AND the SEC is investigating TKTX's disclosures and public filings regarding Replagal and the status of the U.S. Food and Drug Administration's review of the drug, as well as transactions in the company's securities. TKTX in October said it knew about FDA concerns over Replagal at least three days before it released the news to the public. The company on Oct. 2 said the FDA would not approve the drug based on data regarding pain reduction and it would seek approval based on other data, but news of the FDA's decision sent the company's shares plummeting 62 percent. Also, TKTX is being sued for allegedly misleading investors about the effectiveness of its drug.